Literature DB >> 9882303

Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2.

A G Eliopoulos1, S M Blake, J E Floettmann, M Rowe, L S Young.   

Abstract

The transforming Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) activates signalling on the NF-kappaB axis through two distinct domains in its cytoplasmic C terminus, namely, CTAR1 (amino acids [aa] 187 to 231) and CTAR2 (aa 351 to 386). The ability of CTAR1 to activate NF-kappaB appears to be attributable to the direct interaction of tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2), while recent work indicates that CTAR2-induced NF-kappaB is mediated through its association with TNF receptor-associated death domain (TRADD). LMP1 expression also results in activation of the c-Jun N-terminal kinase (JNK) (also known as stress-activated protein kinase) cascade, an effect which is mediated exclusively through CTAR2 and can be dissociated from NF-kappaB induction. The organization and signalling components involved in LMP1-induced JNK activation are not known. In this study we have dissected the extreme C terminus of LMP1 and have identified the last 8 aa of the protein (aa 378 to 386) as being important for JNK signalling. Using a series of fine mutants in which single amino acids between codons 379 and 386 were changed to glycine, we have found that mutations of Pro379, Glu381, Ser383, or Tyr384 diminish the ability of LMP1 CTAR2 to engage JNK signalling. Interestingly, this region was also found to be essential for CTAR2-mediated NF-kappaB induction and coincides with the LMP1 amino acid sequences shown to bind TRADD. Furthermore, we have found that LMP1-mediated JNK activation is synergistically augmented by low levels of TRADD expression, suggesting that this adapter protein is critical for LMP1 signalling. TRAF2 is known to associate with TRADD, and expression of a dominant-negative N-terminal deletion TRAF2 mutant was found to partially inhibit LMP1-induced JNK activation in 293 cells. In addition, the TRAF2-interacting protein A20 blocked both LMP1-induced JNK and NF-kappaB activation, further implicating TRAF2 in these phenomena. While expression of a kinase-inactive mutated NF-kappaB-inducing kinase (NIK), a mitogen-activated protein kinase kinase kinase which also associates with TRAF2, impaired LMP1 signalling on the NF-kappaB axis, it did not inhibit LMP1-induced JNK activation, suggesting that these two pathways may bifurcate at the level of TRAF2. These data further define a role for TRADD and TRAF2 in JNK activation and confirm that LMP1 utilizes signalling mechanisms used by the TNF receptor/CD40 family to elicit its pleiotropic activities.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882303      PMCID: PMC103922     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1).

Authors:  A G Eliopoulos; L S Young
Journal:  Oncogene       Date:  1998-04-02       Impact factor: 9.867

Review 2.  Epstein-Barr virus: LMP1 masquerades as an active receptor.

Authors:  A G Eliopoulos; A B Rickinson
Journal:  Curr Biol       Date:  1998-03-12       Impact factor: 10.834

Review 3.  Viruses and apoptosis.

Authors:  L S Young; C W Dawson; A G Eliopoulos
Journal:  Br Med Bull       Date:  1997       Impact factor: 4.291

4.  A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase.

Authors:  E Hatzivassiliou; W E Miller; N Raab-Traub; E Kieff; G Mosialos
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

5.  Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus.

Authors:  T Mitchell; B Sugden
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade.

Authors:  A Kieser; E Kilger; O Gires; M Ueffing; W Kolch; W Hammerschmidt
Journal:  EMBO J       Date:  1997-11-03       Impact factor: 11.598

7.  TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival.

Authors:  S Y Lee; A Reichlin; A Santana; K A Sokol; M C Nussenzweig; Y Choi
Journal:  Immunity       Date:  1997-11       Impact factor: 31.745

8.  Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice.

Authors:  W C Yeh; A Shahinian; D Speiser; J Kraunus; F Billia; A Wakeham; J L de la Pompa; D Ferrick; B Hum; N Iscove; P Ohashi; M Rothe; D V Goeddel; T W Mak
Journal:  Immunity       Date:  1997-11       Impact factor: 31.745

9.  Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor.

Authors:  E Kilger; A Kieser; M Baumann; W Hammerschmidt
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

10.  Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta.

Authors:  B S Sylla; S C Hung; D M Davidson; E Hatzivassiliou; N L Malinin; D Wallach; T D Gilmore; E Kieff; G Mosialos
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

View more
  76 in total

1.  Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1).

Authors:  K D Brown; B S Hostager; G A Bishop
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

Review 2.  Signaling activities of gammaherpesvirus membrane proteins.

Authors:  B Damania; J K Choi; J U Jung
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 3.  Evolutionary aspects of oncogenic herpesviruses.

Authors:  J Nicholas
Journal:  Mol Pathol       Date:  2000-10

4.  Themed issue: the biology and pathology of the Epstein-Barr virus.

Authors:  P G Murray; L S Young
Journal:  Mol Pathol       Date:  2000-10

5.  Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas.

Authors:  Jingwu Xu; Ali Ahmad; José Menezes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 6.  The expression and function of Epstein-Barr virus encoded latent genes.

Authors:  L S Young; C W Dawson; A G Eliopoulos
Journal:  Mol Pathol       Date:  2000-10

7.  Analysis of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: selection against EBV variants with mutations in the LMP-1 promoter ATF-1/CREB-1 binding site.

Authors:  K Sandvej; B S Andresen; X G Zhou; N Gregersen; S Hamilton-Dutoit
Journal:  Mol Pathol       Date:  2000-10

8.  TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40.

Authors:  Aristides G Eliopoulos; Elyse R Waites; Sarah M S Blake; Clare Davies; Paul Murray; Lawrence S Young
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  A case of Epstein-Barr Virus (EBV)-associated thymic carcinoid and investigation of existence of EBV-infected cells in thymus and thymic tumors.

Authors:  Hiroaki Takeuchi; Hiroshi Fujita; Fumio Iwasaki; Takako Takeuchi; Ken-Ichi Imadome; Toshika Okumiya; Tomohiro Matsui; Mutsuo Takahashi
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Epstein-Barr virus latent membrane protein 1 (LMP-1) half-life in epithelial cells is down-regulated by lytic LMP-1.

Authors:  Jyotsna Pandya; Dennis M Walling
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.